Clinical Trial

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Study acronym: PRISM-MEL-301
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2023-10-31; most recent amendment 2026-02-23.
Status change: Not Yet Recruiting → Recruiting 2024-02-15
Trial Details
NCT Number NCT06112314
Lead Sponsor Immunocore Ltd
Conditions Advanced Melanoma
Enrollment 680 participants
Start Date 2024-06-05
Primary Completion 2027-10-16 (estimated)
Study Completion 2027-10-16 (estimated)
Updated on ClinicalTrials.gov 2026-02-25